Literature DB >> 8667222

Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier.

A Kakee1, T Terasaki, Y Sugiyama.   

Abstract

A brain efflux index method has been developed to characterize an efflux transport system for substrates from the cerebrum to the circulating blood across the blood-brain barrier. The brain efflux index value is defined as the relative amount of test drug effluxed from cerebrum compared with that of a reference compound, [14C]carboxylinulin, which has limited blood-brain barrier permeability. Microinjection of 0.2, 0.5 or 1.0 microliter into the parietal cortex area 2 region was found to be an appropriate procedure for obtaining a high recovery and for restricting the test drug and reference compound to the ipsilateral cerebrum. No significant increase in influx clearance of [14C]carboxylinulin into the brain was observed for the ipsilateral cerebrum after the sham microinjection compared with the contralateral cerebrum, which demonstrated that only limited physical damage is caused. Microinjection of [3H]H2O into the cerebrum devoid of cerebral blood flow yielded no elimination from the brain. Analysis based on a pharmacokinetic model demonstrated that the elimination of a highly permeable compound [3H]H2O from the brain was governed by cerebral blood flow. The apparent elimination rate constant (Kel) of [3H]3-O-methyl-D-glucose from the brain was determined as 0.129 +/- 0.014 (min-1) and was reduced significantly by a preinjection of excess cold 3-O-methyl-D-glucose and phloridzin, whereas no significant elimination was observed for L[3H]glucose. The efflux clearance of 3-O-methyl-D-glucose was calculated from the Kel value and the compound's distribution volume, the value being close to that of the influx clearance. These results demonstrate that the brain efflux index method is a useful technique for analyzing an efflux process from the brain across the blood-brain barrier involving a carrier-mediated transport system.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8667222

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  50 in total

1.  Enhanced brain amyloid-β clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease.

Authors:  Hisham Qosa; Alaa H Abuznait; Ronald A Hill; Amal Kaddoumi
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 2.  Brain-to-blood transporters for endogenous substrates and xenobiotics at the blood-brain barrier: an overview of biology and methodology.

Authors:  Tetsuya Terasaki; Sumio Ohtsuki
Journal:  NeuroRx       Date:  2005-01

3.  Contributions of degradation and brain-to-blood elimination across the blood-brain barrier to cerebral clearance of human amyloid-β peptide(1-40) in mouse brain.

Authors:  Shingo Ito; Kohta Matsumiya; Sumio Ohtsuki; Junichi Kamiie; Tetsuya Terasaki
Journal:  J Cereb Blood Flow Metab       Date:  2013-08-21       Impact factor: 6.200

4.  Reduction of brain beta-amyloid (Abeta) by fluvastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, through increase in degradation of amyloid precursor protein C-terminal fragments (APP-CTFs) and Abeta clearance.

Authors:  Mitsuru Shinohara; Naoyuki Sato; Hitomi Kurinami; Daisuke Takeuchi; Shuko Takeda; Munehisa Shimamura; Toshihide Yamashita; Yasuo Uchiyama; Hiromi Rakugi; Ryuichi Morishita
Journal:  J Biol Chem       Date:  2010-05-14       Impact factor: 5.157

5.  Atrial natriuretic peptide is eliminated from the brain by natriuretic peptide receptor-C-mediated brain-to-blood efflux transport at the blood-brain barrier.

Authors:  Shingo Ito; Sumio Ohtsuki; Yuki Katsukura; Miho Funaki; Yusuke Koitabashi; Akihiko Sugino; Sho Murata; Tetsuya Terasaki
Journal:  J Cereb Blood Flow Metab       Date:  2010-07-14       Impact factor: 6.200

Review 6.  Drug transport across the blood-brain barrier.

Authors:  William M Pardridge
Journal:  J Cereb Blood Flow Metab       Date:  2012-08-29       Impact factor: 6.200

Review 7.  Diffusion of macromolecules in the brain: implications for drug delivery.

Authors:  Daniel J Wolak; Robert G Thorne
Journal:  Mol Pharm       Date:  2013-01-31       Impact factor: 4.939

8.  The role of permeability in drug ADME/PK, interactions and toxicity--presentation of a permeability-based classification system (PCS) for prediction of ADME/PK in humans.

Authors:  Urban Fagerholm
Journal:  Pharm Res       Date:  2007-08-21       Impact factor: 4.200

Review 9.  Manganese flux across the blood-brain barrier.

Authors:  Robert A Yokel
Journal:  Neuromolecular Med       Date:  2009-11-10       Impact factor: 3.843

Review 10.  Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications.

Authors:  P Kannan; C John; S S Zoghbi; C Halldin; M M Gottesman; R B Innis; M D Hall
Journal:  Clin Pharmacol Ther       Date:  2009-07-22       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.